These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 32112041)

  • 1. Synaptic and cellular plasticity in Parkinson's disease.
    Chu HY
    Acta Pharmacol Sin; 2020 Apr; 41(4):447-452. PubMed ID: 32112041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia.
    Prescott IA; Liu LD; Dostrovsky JO; Hodaie M; Lozano AM; Hutchison WD
    Neurobiol Dis; 2014 Nov; 71():24-33. PubMed ID: 25116960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Roles of Microglia in the Basal Ganglia in Parkinson's Disease.
    Choudhury ME; Kigami Y; Tanaka J
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substantia nigra control of basal ganglia nuclei.
    Guatteo E; Cucchiaroni ML; Mercuri NB
    J Neural Transm Suppl; 2009; (73):91-101. PubMed ID: 20411770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synaptic dysfunction in Parkinson's disease.
    Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
    Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and Synaptic Dysfunctions in Parkinson's Disease: Stepping out of the Striatum.
    Mallet N; Delgado L; Chazalon M; Miguelez C; Baufreton J
    Cells; 2019 Aug; 8(9):. PubMed ID: 31470672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects of glutamate antagonists in the therapy of Parkinson's disease.
    Blandini F; Greenamyre JT
    Fundam Clin Pharmacol; 1998; 12(1):4-12. PubMed ID: 9523179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuronal inhibition and synaptic plasticity of basal ganglia neurons in Parkinson's disease.
    Milosevic L; Kalia SK; Hodaie M; Lozano AM; Fasano A; Popovic MR; Hutchison WD
    Brain; 2018 Jan; 141(1):177-190. PubMed ID: 29236966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The endocannabinoid system in Parkinson's disease.
    Di Filippo M; Picconi B; Tozzi A; Ghiglieri V; Rossi A; Calabresi P
    Curr Pharm Des; 2008; 14(23):2337-47. PubMed ID: 18781984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson's disease.
    Benazzouz A; Mamad O; Abedi P; Bouali-Benazzouz R; Chetrit J
    Front Aging Neurosci; 2014; 6():87. PubMed ID: 24860498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamate receptors as therapeutic targets for Parkinson's disease.
    Johnson KA; Conn PJ; Niswender CM
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):475-91. PubMed ID: 19702565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders.
    Rouse ST; Marino MJ; Bradley SR; Awad H; Wittmann M; Conn PJ
    Pharmacol Ther; 2000 Dec; 88(3):427-35. PubMed ID: 11337032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anatomy of the dopamine system in the basal ganglia.
    Smith Y; Kieval JZ
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S28-33. PubMed ID: 11052217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa Effect on Basal Ganglia Motor Circuit in Parkinson's Disease.
    Gao LL; Zhang JR; Chan P; Wu T
    CNS Neurosci Ther; 2017 Jan; 23(1):76-86. PubMed ID: 27663605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
    Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
    Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains.
    Smith Y; Villalba R
    Mov Disord; 2008; 23 Suppl 3():S534-47. PubMed ID: 18781680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the globus pallidus in motor and non-motor symptoms of Parkinson's disease.
    Jiang Y; Qi Z; Zhu H; Shen K; Liu R; Fang C; Lou W; Jiang Y; Yuan W; Cao X; Chen L; Zhuang Q
    Neural Regen Res; 2025 Jun; 20(6):1628-1643. PubMed ID: 38845220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional changes of the basal ganglia circuitry in Parkinson's disease.
    Blandini F; Nappi G; Tassorelli C; Martignoni E
    Prog Neurobiol; 2000 Sep; 62(1):63-88. PubMed ID: 10821982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.